fabry disease

基本解释

Ironically, the agency encouraged Shire to enter the Fabry disease market in the US in the wake of protracted quality-control problems encountered by Genzyme.
FORBES: Shire Ends Fabry Drug Bid, Giving Sanofi A Boost
Fabrazyme treats Fabry disease, which afflicts some 3, 000 patients worldwide.
FORBES: Magazine Article
In a surprise move, Shire Pharmaceuticals has ended its bid for FDA approval for its Replagal biologic for treating Fabry disease, a rare, but life-threatening genetic disorder.
FORBES: Shire Ends Fabry Drug Bid, Giving Sanofi A Boost